3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

Impact · against what's priced in

The article provides no new catalysts for Halozyme Therapeutics, as the highlighted EPS growth projections are already captured in the current valuation and raised 2026 guidance.

HALO+0.00

Already priced in

The price assumes

The raised full-year 2026 guidance, including the $975M-$1.02B revenue range and $3.10-$3.30 EPS

The article highlights a projected EPS growth of 112.1% for the year, but the market already assumes the delivery of the raised 2026 guidance ($3.10-$3.30 EPS).